<DOC>
	<DOCNO>NCT01472939</DOCNO>
	<brief_summary>The aim study establish dose-related effect selective 5-HT4 receptor agonist compare placebo residual symptom ( regurgitation without heartburn ) subject GERD persistent symptom PPI therapy .</brief_summary>
	<brief_title>Selective 5-HT4 Receptor Agonist Proton Pump Inhibitor ( PPI ) Subjects With Gastroesophageal Reflux Disease ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>1 . Written Informed Consent Form sign voluntarily first studyrelated activity . 2 . Aged 18 70 year , inclusive . 3 . Subjects history cardinal symptom GERD ( heartburn regurgitation ) prior PPI therapy . 4 . Subjects symptoms GERD least 6 month prior Screening Visit . 5 . Subjects persistent symptom regurgitation 3 day past week without heartburn PPI . 6 . Subjects least improvement symptom heartburn PPI therapy . 7 . Subjects PPI therapy least 8 week prior Screening Visit last 4 week stable label dose GERD indication accord country label , change PPI therapy would impact symptom ( twicedaily dose PPI allow last 4 week ) 1 . Subjects show response heartburn PPI therapy . 2 . Subjects dyspepsia symptom predominant GERD symptom ( heartburn and/or regurgitation ) . 3 . Subjects prior endoscopic antireflux procedure major GI surgery subject major GI disorder . 4 . Presence severe clinically uncontrolled cardiovascular , liver , lung neurologic disease , cancer AIDS . 5 . Alarm symptom suggestive malignancy organic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>